Cardiovascular Safety Study of Lodenafil Carbonate in Patients With Coronaropathy During Physical Effort
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00817830 |
Recruitment Status :
Withdrawn
(Difficulty in patient recruitment)
First Posted : January 7, 2009
Last Update Posted : July 16, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Erectile Dysfunction Coronaropathy | Drug: lodenafil carbonate | Phase 4 |
Phosphodiesterase 5 inhibitors (iPDE5) are effective drugs to treat erectile dysfunction (ED).
ED is linked to several factors, like advanced age and diabetes as predominant in its incidence. In addition, ED can be an early manifestation of cardiovascular diseases.
Among the iPDE5 existing in the Brazilian market there is a new molecule which called lodenafil carbonate. It was recently approve and release for use in Brazil, and has similar effectiveness and adverse reactions comparing with other drugs from the same family.
The molecule was evaluated with respect to possible changes in heart rate, blood pressure and QT interval, and the results point out excellent cardiovascular safety profile.
There is a corelated incidence between patients with coronary artery disease and erectile dysfunction. Although patients with stable angina and, under appropriate clinical treatment did not show increase in cardiovascular risks during sexual intercourse, the increased incidence of erectile dysfunction in this population determines a specific group of patients with high potential for use iPDE5.
Therefore it is essential that any new phosphodiesterase 5 inhibitors should be evaluated in patients with coronary artery disease, especially in heart rate, during physical effort.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate |
Study Start Date : | November 2008 |
Primary Completion Date : | May 2009 |
Study Completion Date : | October 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: lodenafil carbonate
Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
|
Drug: lodenafil carbonate
Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
Other Name: Helleva |
- Evaluate changes in effort test showing the safety of lodenafil carbonate in patients with coronaropathy. [ Time Frame: july 2009 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Coronary artery disease with obstruction <70%, confirmed by prior catheterization, stable patient, and have already showed an acute event (unstable angina or myocardial infarction, according to the guidelines of the Brazilian Society of Cardiology) for at least 6 months;
- Age ≥ 18 and ≤ 60;
- Men;
- Stable for 6 months, regardless of previous myocardial infarction or revascularization;
- ejection fraction of doppler echocardiography ≥ 50%.
Exclusion Criteria:
- Use of nitrate;
- Use of bronchodilators;
- Smoking current period or in less than 6 months;
- Hemoglobin <10 g / dL;
- Systolic pressure> 160 mm Hg and <100 mmHg;
- Diastolic pressure> 110 mm Hg and <60 mmHg;
- Body mass index (BMI)> 30;
- Symptomatic peripheral artery disease;
- Event of angina or AMI, at any time, whether I've done some examination or not;
- Finger tip blood glucose < 70 and > 200mg/dL at the time of examination;
- Chest injury > 50%;
- Triple arterial injury with surgery indication;
- Moderate or severe chronic obstructive pulmonary disease (COPD) confirmed by spirometry;
- Pulmonary hypertension with pressure > 35mmHg confirmed by doppler echocardiography;
- Moderate or important aortic and/or mitral valvulopathy confirmed by doppler echocardiography;
- Changes in enzyme markers (Troponin I) after the first test;

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00817830
Brazil | |
Irmandade da Santa Casa de Misericórdia de São Paulo | |
São Paulo, Brazil |
Principal Investigator: | Roberto Franken, Doctor | Irmandade da Santa Casa de Misericórdia de São Paulo |
Responsible Party: | Dr. Jorge Barros Afiune, Cristália Pordutos Químicos Farmacêuticos Ltda |
ClinicalTrials.gov Identifier: | NCT00817830 |
Other Study ID Numbers: |
CRIST001 |
First Posted: | January 7, 2009 Key Record Dates |
Last Update Posted: | July 16, 2015 |
Last Verified: | June 2011 |
Coronaropathy lodenafil carbonate Erectile dysfunction Treatment QT interval |
Phosphodiesterase inhibitors Cardiac arrhythmia Effort testPhosphodiesterase 5 inhibitors Cardiovascular test |
Erectile Dysfunction Coronary Artery Disease Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Mental Disorders Coronary Disease |
Myocardial Ischemia Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |